Diversified Trust Co. Has $1.40 Million Stake in Incyte Corporation $INCY

Diversified Trust Co. reduced its holdings in Incyte Corporation (NASDAQ:INCY) by 37.2% during the 4th quarter, HoldingsChannel reports. The firm owned 14,135 shares of the biopharmaceutical company’s stock after selling 8,360 shares during the quarter. Diversified Trust Co.’s holdings in Incyte were worth $1,396,000 as of its most recent filing with the SEC.

A number of other institutional investors have also made changes to their positions in the business. Arrowstreet Capital Limited Partnership lifted its position in shares of Incyte by 701.8% during the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 2,730,648 shares of the biopharmaceutical company’s stock worth $185,957,000 after purchasing an additional 2,390,084 shares during the last quarter. AQR Capital Management LLC boosted its position in shares of Incyte by 21.8% in the second quarter. AQR Capital Management LLC now owns 8,201,455 shares of the biopharmaceutical company’s stock valued at $558,519,000 after acquiring an additional 1,465,286 shares during the period. Norges Bank bought a new stake in shares of Incyte in the second quarter valued at approximately $96,776,000. Pacer Advisors Inc. grew its stake in shares of Incyte by 8,091.6% in the third quarter. Pacer Advisors Inc. now owns 1,248,642 shares of the biopharmaceutical company’s stock worth $105,897,000 after acquiring an additional 1,233,399 shares during the last quarter. Finally, Marshall Wace LLP acquired a new stake in shares of Incyte in the second quarter worth $82,485,000. 96.97% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In related news, EVP Mohamed Khairie Issa sold 10,856 shares of the company’s stock in a transaction dated Wednesday, January 7th. The shares were sold at an average price of $109.07, for a total value of $1,184,063.92. Following the sale, the executive vice president owned 66,132 shares of the company’s stock, valued at $7,213,017.24. The trade was a 14.10% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Pablo J. Cagnoni sold 18,667 shares of the stock in a transaction dated Tuesday, March 17th. The stock was sold at an average price of $94.24, for a total transaction of $1,759,178.08. Following the completion of the transaction, the insider directly owned 234,800 shares of the company’s stock, valued at $22,127,552. This trade represents a 7.36% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 17.80% of the company’s stock.

Analyst Ratings Changes

Several equities analysts recently commented on INCY shares. TD Cowen reiterated a “buy” rating on shares of Incyte in a research note on Tuesday, January 13th. Wells Fargo & Company decreased their price target on shares of Incyte from $107.00 to $101.00 and set an “equal weight” rating on the stock in a research report on Wednesday, February 11th. Jefferies Financial Group downgraded shares of Incyte from a “buy” rating to a “hold” rating and dropped their price objective for the stock from $120.00 to $94.00 in a report on Monday, March 16th. The Goldman Sachs Group reaffirmed a “neutral” rating and set a $90.00 price objective on shares of Incyte in a research report on Thursday, January 8th. Finally, Barclays reiterated an “overweight” rating on shares of Incyte in a research note on Tuesday. Nine equities research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $104.89.

Trending Headlines about Incyte

Here are the key news stories impacting Incyte this week:

• Positive Sentiment: HC Wainwright reaffirmed a “buy” rating and lifted its price target to $135, signalling strong analyst conviction and providing notable upside potential relative to the current share level. Article Title
• Neutral Sentiment: Incyte announced executive leadership appointments — a corporate governance update that may be viewed positively if it strengthens execution but is unlikely to move fundamentals immediately. Incyte Announces Executive Leadership Appointments
• Neutral Sentiment: Coverage piece assessing Incyte’s valuation after mixed short-term returns and strong one‑year performance — useful context for investors but not a direct near-term catalyst. A Look At Incyte (INCY) Valuation
• Neutral Sentiment: Multiple reports flagged a “significant” rise in short interest for March, but published figures show zero shares and NaN changes — likely a data/reporting anomaly. Investors should treat the short-interest headlines cautiously and monitor clearer data from exchanges.
• Negative Sentiment: UBS cut its price target from $104 to $94 and moved to a “neutral” rating, which narrows perceived upside and can weigh on sentiment among more conservative investors. Article Title
• Neutral Sentiment: A sector competitor (Karyopharm) reported mixed Phase 3 trial data in myelofibrosis — a development that may shift sector sentiment or competitive positioning but has uncertain direct impact on Incyte’s pipeline. Karyopharm myeloma drug yields mixed data in myelofibrosis trial

Incyte Stock Performance

Shares of NASDAQ INCY opened at $92.23 on Thursday. The business has a fifty day simple moving average of $99.56 and a 200 day simple moving average of $96.94. The company has a current ratio of 3.32, a quick ratio of 3.25 and a debt-to-equity ratio of 0.01. The firm has a market capitalization of $18.35 billion, a price-to-earnings ratio of 14.39, a PEG ratio of 0.72 and a beta of 0.84. Incyte Corporation has a one year low of $53.56 and a one year high of $112.29.

Incyte (NASDAQ:INCY) last issued its earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.80 EPS for the quarter, missing the consensus estimate of $1.96 by ($0.16). The firm had revenue of $1.51 billion during the quarter, compared to the consensus estimate of $1.35 billion. Incyte had a return on equity of 26.34% and a net margin of 25.03%.The firm’s revenue for the quarter was up 27.8% compared to the same quarter last year. During the same period last year, the business earned $1.43 earnings per share. Sell-side analysts expect that Incyte Corporation will post 4.86 EPS for the current year.

About Incyte

Incyte Corporation is a Wilmington, Delaware–based biopharmaceutical company focused on the discovery, development and commercialization of novel therapies in oncology and inflammation. Since its founding in 2002, Incyte has grown from a small research organization into a global enterprise, advancing a portfolio of internally developed and partnered assets. The company’s research and development efforts center on small-molecule drugs and biologics that modulate critical signaling pathways implicated in cancer, autoimmune disorders and rare diseases.

The company’s flagship product is Jakafi® (ruxolitinib), a Janus kinase (JAK) inhibitor approved for the treatment of myelofibrosis and polycythemia vera.